---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-250137"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-09-23T23:59:59+00:00"
generated_at: "2026-06-23T07:41:40.133067+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# CytomX Therapeutics CFO Carlos Campoy to depart Sept 30; Chris Ogden named principal financial officer

## Summary
- Carlos Campoy, SVP and CFO, expected to terminate employment effective Sept 30, 2022.
- Chris Ogden, SVP Finance and Accounting, assumes principal financial and principal accounting officer roles effective immediately.
- Ogden's biographical details incorporated by reference from April 2022 proxy statement.
- No family relationships or related party transactions between Ogden and the Company.

## SEC filing metadata
- accession: 0001193125-22-250137
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-09-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312522250137/0001193125-22-250137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312522250137/d401274d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-250137
- JSON: https://secwatch.observer/filing/0001193125-22-250137.json
- Plain text: https://secwatch.observer/filing/0001193125-22-250137.txt

## Key facts
- Executive change
  Carlos Campoy departed as SVP, Chief Financial Officer at CytomX Therapeutics, Inc..
  - Action: planned departure
  - Role: SVP, Chief Financial Officer
  source text: the planned departure of Carlos Campoy, the Company's SVP, Chief Financial Officer and former principal financial officer and principal accounting officer, whose employment is expected to terminate effective as of September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522250137/0001193125-22-250137-index.htm
- Executive change
  Chris Ogden was appointed as Principal Financial Officer and Principal Accounting Officer at CytomX Therapeutics, Inc..
  - Action: designated
  - Role: Principal Financial Officer and Principal Accounting Officer
  source text: designated Chris Ogden, the Company's Senior Vice President, Finance and Accounting, to assume the responsibilities of principal financial officer and principal accounting officer, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312522250137/0001193125-22-250137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.